Actively Recruiting
Phase 3 Trial of Deucravacitinib Versus Placebo in Children and Adolescents With Active Juvenile Psoriatic Arthritis
Led by Bristol-Myers Squibb · Updated on 2026-10-06
60
Participants Needed
48
Research Sites
51 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating Deucravacitinib BMS-986165 in children and adolescents aged 5 to less than 18 years with juvenile psoriatic arthritis. This phase 3 trial aims to study the drug levels, effectiveness, and safety of this treatment in pediatric patients with active disease who have tried other medicines with limited success or problems. Participants are randomly assigned to receive either Deucravacitinib or a placebo following a specified dosing schedule. The study includes a withdrawal period from week 16 to week 42 to assess the time to first flare and other disease activity measures. The trial is double-blind and placebo-controlled, meaning neither participants nor researchers know who receives the active drug or placebo during the study. During the trial, participants undergo assessments including joint evaluations, disease activity scores, psoriasis severity indexes, and monitoring for adverse events. Blood samples are collected to measure drug concentrations and response. The study also evaluates participants ability to swallow the medication and their taste preferences. Safety and efficacy are closely monitored through week 42, with the option for continued observation until the study ends in 2031.
CONDITIONS
Brief Title
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
Research Team
B
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
F
First line of the email MUST contain NCT # and Site #.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here